| Year |
Citation |
Score |
| 2022 |
Pennell CA, Campbell H, Storlie MD, Bolivar-Wagers S, Osborn MJ, Refaeli Y, Jensen M, Viaud S, Young TS, Blazar BR. Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19 malignancy. Journal For Immunotherapy of Cancer. 10. PMID 36521930 DOI: 10.1136/jitc-2022-005934 |
0.677 |
|
| 2018 |
Viaud S, Ma JSY, Hardy IR, Hampton EN, Benish B, Sherwood L, Nunez V, Ackerman CJ, Khialeeva E, Weglarz M, Lee SC, Woods AK, Young TS. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proceedings of the National Academy of Sciences of the United States of America. PMID 30373813 DOI: 10.1073/Pnas.1810060115 |
0.503 |
|
| 2018 |
Huang H, Viaud S, Theofilopoulos AN, Young TS, Kono DH. AI-04 Immunotherapy for lupus in a mouse model to define pathogenesis and therapeutic targeting Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Lsm.4 |
0.634 |
|
| 2016 |
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, ... ... Viaud S, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 5: e1071008. PMID 27141373 DOI: 10.1080/2162402X.2015.1071008 |
0.312 |
|
| 2014 |
Pitt JM, Charrier M, Viaud S, André F, Besse B, Chaput N, Zitvogel L. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. Journal of Immunology (Baltimore, Md. : 1950). 193: 1006-11. PMID 25049431 DOI: 10.4049/jimmunol.1400703 |
0.312 |
|
| 2014 |
Viaud S, Daillère R, Boneca IG, Lepage P, Langella P, Chamaillard M, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L. Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death and Differentiation. 22: 199-214. PMID 24832470 DOI: 10.1038/cdd.2014.56 |
0.402 |
|
| 2014 |
Viaud S, Daillère R, Yamazaki T, Lepage P, Boneca I, Goldszmid R, Trinchieri G, Zitvogel L. Why should we need the gut microbiota to respond to cancer therapies? Oncoimmunology. 3: e27574. PMID 24800167 DOI: 10.4161/onci.27574 |
0.493 |
|
| 2013 |
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, N.Y.). 342: 971-6. PMID 24264990 DOI: 10.1126/Science.1240537 |
0.332 |
|
| 2013 |
Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, Zitvogel L. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death and Differentiation. 21: 50-8. PMID 23744294 DOI: 10.1038/cdd.2013.60 |
0.458 |
|
| 2011 |
Viaud S, Ploix S, Lapierre V, Théry C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O, Zitvogel L, Chaput N. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 65-75. PMID 21150714 DOI: 10.1097/CJI.0b013e3181fe535b |
0.441 |
|
| 2011 |
Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Research. 71: 661-5. PMID 21148486 DOI: 10.1158/0008-5472.CAN-10-1259 |
0.497 |
|
| 2010 |
Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Research. 70: 1281-5. PMID 20145139 DOI: 10.1158/0008-5472.CAN-09-3276 |
0.393 |
|
| 2009 |
Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. Plos One. 4: e4942. PMID 19319200 DOI: 10.1371/journal.pone.0004942 |
0.457 |
|
| 2008 |
Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene. 27: 5920-31. PMID 18836473 DOI: 10.1038/onc.2008.270 |
0.36 |
|
| 2008 |
Viaud S, Ullrich E, Zitvogel L, Chaput N. Exosomes for the treatment of human malignancies. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 40: 82-8. PMID 18283625 DOI: 10.1055/s-2007-1022548 |
0.425 |
|
| 2007 |
Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Ménard C, Viaud S, Tursz T, Kroemer G, Zitvogel L. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Research. 67: 851-3. PMID 17283111 DOI: 10.1158/0008-5472.Can-06-3766 |
0.304 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2006 |
Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, André F, LePecq JB, Boussac M, Garin J, Amigorena S, Théry C, Zitvogel L. Dendritic cell derived-exosomes: biology and clinical implementations. Journal of Leukocyte Biology. 80: 471-8. PMID 16809645 DOI: 10.1189/jlb.0206094 |
0.298 |
|
| 2006 |
Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, Viaud S, Zitvogel L, Kroemer G. Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Annals of the New York Academy of Sciences. 1090: 35-49. PMID 17384245 DOI: 10.1196/Annals.1378.004 |
0.293 |
|
| 2012 |
Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Research. 72: 2757-67. PMID 22427351 DOI: 10.1158/0008-5472.Can-11-3379 |
0.274 |
|
| 2015 |
Goldszmid RS, Dzutsev A, Viaud S, Zitvogel L, Restifo NP, Trinchieri G. Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunology Research. 3: 103-9. PMID 25660553 DOI: 10.1158/2326-6066.Cir-14-0225 |
0.272 |
|
| 2014 |
Viaud S, Daillère R, Boneca IG, Lepage P, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L. Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Research. 74: 4217-21. PMID 25074615 DOI: 10.1158/0008-5472.CAN-14-0987 |
0.264 |
|
| 2011 |
Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N. An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae. Cell Cycle (Georgetown, Tex.). 10: 118-26. PMID 21200142 DOI: 10.4161/Cc.10.1.14445 |
0.237 |
|
| 2006 |
Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G. Macrophage activation switching: an asset for the resolution of inflammation. Clinical and Experimental Immunology. 142: 481-9. PMID 16297160 DOI: 10.1111/j.1365-2249.2005.02934.x |
0.217 |
|
| 2010 |
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Research. 70: 490-500. PMID 20068181 DOI: 10.1158/0008-5472.Can-09-1890 |
0.184 |
|
| 2009 |
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Chaput N, Andre F, Kroemer G, Zitvogel L. Anticancer effects of polyadenylic-polyuridylic acid (poly[A:U]) and uncoupling of chemokine receptor signaling: Role of CCR5 and CXCR3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3063. PMID 27962015 DOI: 10.1200/Jco.2009.27.15_Suppl.3063 |
0.182 |
|
| 2019 |
Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL, Mendoza D, Rodriguez-Aguirre ME, Bergqvist S, Haghighi A, Miner MV, Accomando WP, Burrascano C, Gammon D, Gruber HE, et al. PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget. 10: 2252-2269. PMID 31040917 DOI: 10.18632/Oncotarget.26785 |
0.164 |
|
| 2011 |
Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Research. 71: 5393-9. PMID 21724589 DOI: 10.1158/0008-5472.Can-11-0993 |
0.132 |
|
| 2012 |
Viaud S, Maynard L, Sanquer A. Comparison of two shampoos as sole treatment for canine bacterial overgrowth syndrome. The Veterinary Record. 170: 675. PMID 22678617 DOI: 10.1136/vr.100643 |
0.103 |
|
| 2015 |
Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. European Journal of Immunology. 45: 17-31. PMID 25328099 DOI: 10.1002/eji.201444972 |
0.09 |
|
| 2015 |
Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Science Translational Medicine. 7: 271ps1. PMID 25609166 DOI: 10.1126/Scitranslmed.3010473 |
0.08 |
|
| 2013 |
Hannani D, Vétizou M, Enot D, Rusakiewicz S, Viaud S, Klazmann D, Chaput N, Eggermont A, Kroemer G, Robert C, Zitvogel L. Modes of action of ipilimumab and biomarkers of resistance to therapy in patients Annales De Dermatologie Et De VéNéRéOlogie. 140: S627-S628. DOI: 10.1016/J.Annder.2013.09.653 |
0.039 |
|
| 2011 |
Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology. 33: 369-83. PMID 21611872 DOI: 10.1007/s00281-011-0245-0 |
0.033 |
|
| Hide low-probability matches. |